Acadia Pharmaceuticals (ACAD) Liabilities and Shareholders Equity (2010 - 2026)

Acadia Pharmaceuticals has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $1.6 billion in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 41.76% year-over-year to $1.6 billion; the trailing twelve-month figure through Mar 2026 stood at $5.7 billion (up 35.97% YoY), and the FY2025 full-year result was $1.6 billion, up 31.69% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $1.6 billion, up from $1.6 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $1.6 billion in Q1 2026, with the low at $587.8 million in Q4 2022.
• Average Liabilities and Shareholders Equity over 5 years is $935.2 million, with a median of $855.1 million recorded in 2024.
• Year-over-year, Liabilities and Shareholders Equity retreated 17.34% in 2022 and soared 58.59% in 2024.
• Tracing ACAD's Liabilities and Shareholders Equity over 5 years: stood at $587.8 million in 2022, then increased by 27.41% to $749.0 million in 2023, then soared by 58.59% to $1.2 billion in 2024, then surged by 31.69% to $1.6 billion in 2025, then rose by 2.62% to $1.6 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.6 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.

Peer Comparison